Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Staphylococcus aureus is considered to be an extracellular pathogen. However, survival of S. aureus within host cells may provide a reservoir relatively protected from antibiotics, thus enabling long-term colonization of the host and explaining clinical failures and relapses after antibiotic therapy. Here we confirm that intracellular reservoirs of S. aureus in mice comprise a virulent subset of bacteria that can establish infection even in the presence of vancomycin, and we introduce a novel therapeutic that effectively kills intracellular S. aureus. This antibody-antibiotic conjugate consists of an anti-S. aureus antibody conjugated to a highly efficacious antibiotic that is activated only after it is released in the proteolytic environment of the phagolysosome. The antibody-antibiotic conjugate is superior to vancomycin for treatment of bacteraemia and provides direct evidence that intracellular S. aureus represents an important component of invasive infections.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the Ab-rifalogue complex was more effective than uncoupled antibiotics in combating infection in an in vivo mouse model.”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [126]
In the citing paper
“intracellular MRSA represent an important pathogen reservoir that is shielded from antibiotic action.”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [126]
In the citing paper
“Mice challenged with infected cells rather than bacterial particles, were shown to present higher bacterial burdens despite vancomycin treatment [126].”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [126]
In the citing paper
“rifalogue was conjugated to an S. aureus-specific antibody via a cleavable bridge so that opsonized MRSA, once phagocytosed, could be effectively killed by the protease-liberated antibiotic.”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [126]
Citations
Cites
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,005
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Diekema, D. J., Pfaller, M. A., Schmitz, F. J., Smayevsky, J., Bell, J., Jones, R. N., Beach, M., & SENTRY Participants Group (2001) · Clinical Infectious Diseases · doi:10.1086/320184 · Cited by 1,362
Activated ClpP kills persisters and eradicates a chronic biofilm infection
Conlon, B. P., Nakayasu, E. S., Fleck, L. E., LaFleur, M. D., Isabella, V. M., Coleman, K., Leonard, S. N., Smith, R. D., Adkins, J. N., & Lewis, K. (2013) · Nature · doi:10.1038/nature12790 · Cited by 672
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Monk, I. R., Shah, I. M., Xu, M., Tan, M.-W., & Foster, T. J. (2012) · mBio · doi:10.1128/mbio.00277-11 · Cited by 542
Cited by
Antibiotics: past, present and future
Hutchings, M. I., Truman, A. W., & Wilkinson, B. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.10.008 · Cited by 2,370
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
“Such a scenario was recently illustrated by Lehar and colleagues, who showed that, compared to extracellular planktonic bacteria, intracellular MRSA isolates exhibit a 100-fold increase in the vancomycin MIC, as well as an enhanced propensity for systemic dissemination in an antibiotic-treated mouse infection model (2…”
BackgroundMethicillin-resistant Staphylococcus aureus
Lee, A. S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-Kumar, S., Peschel, A., & Harbarth, S. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.33 · Cited by 1,556
Persistent bacterial infections and persister cells
Fisher, R. A., Gollan, B., & Helaine, S. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.42 · Cited by 1,243
Defining and combating antibiotic resistance from One Health and Global Health perspectives
Hernando-Amado, S., Coque, T. M., Baquero, F., & Martínez, J. L. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0503-9 · Cited by 1,224
Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer
Fu, A., Yao, B., Dong, T., Chen, Y., Yao, J., Liu, Y., Li, H., Bai, H., Liu, X., Zhang, Y., et al. (2022) · Cell · doi:10.1016/j.cell.2022.02.027 · Cited by 981
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease
Becattini, S., Taur, Y., & Pamer, E. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.003 · Cited by 901
“In this study, rifalogue was conjugated to an S. aureus-specific antibody via a cleavable bridge such that opsonized MRSA, once phagocytosed, could be effectively killed by the protease-liberated antibiotic.”
BackgroundInfluentialAntibiotic resistance and persistence—implications for human health and treatment perspectives
Huemer, M., Mairpady Shambat, S., Brugger, S. D., & Zinkernagel, A. S. (2020) · The EMBO Reports · doi:10.15252/embr.202051034 · Cited by 850
“In addition, intracellularly residing S. aureus (Dziewanowska et al , 1999; Jevon et al , 1999; Fraunholz & Sinha, 2012; Lehar et al , 2015) are protected from vancomycin and may be another reason for vancomycin treatment failure.”
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Multidrug evolutionary strategies to reverse antibiotic resistance
Baym, M., Stone, L. K., & Kishony, R. (2016) · Science · doi:10.1126/science.aad3292 · Cited by 710
“Several complementary strategies for evolutionarily robust bacterial inhibition have been suggested, including suppression of virulence (21–23), persistence (24), and quorum sensing (25, 26), as well as novel targeting strategies to allow higher effective doses (27); however, they are outside the scope of this review.”
Antimicrobial resistance: a concise update
Ho, C. S., Wong, C. T. H., Aung, T. T., Lakshminarayanan, R., Mehta, J. S., Rauz, S., McNally, A., Kintses, B., Peacock, S. J., de la Fuente-Nunez, C., et al. (2025) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.07.010 · Cited by 634
Sakr, A., Brégeon, F., Mège, J.-L., Rolain, J.-M., & Blin, O. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02419 · Cited by 555
“In this study, intracellular bacteria were able to establish infection even in the presence of this antibiotic (Lehar et al., 2015), whereas planktonic bacteria were eliminated by vancomycin and did not cause infection.”
BackgroundContemporary approaches to site-selective protein modification
Hoyt, E. A., Cal, P. M. S. D., Oliveira, B. L., & Bernardes, G. J. L. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0079-1 · Cited by 537
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Rejuvenated Photodynamic Therapy for Bacterial Infections
Jia, Q., Song, Q., Li, P., & Huang, W. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201900608 · Cited by 426
Kang, M., Zhou, C., Wu, S., Yu, B., Zhang, Z., Song, N., Lee, M. M. S., Xu, W., Xu, F.-J., Wang, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b07162 · Cited by 414
Antibody–drug conjugates: Recent advances in linker chemistry
Su, Z., Xiao, D., Xie, F., Liu, L., Wang, Y., Fan, S., Zhou, X., & Li, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.042 · Cited by 403
Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy
Hussain, S., Joo, J., Kang, J., Kim, B., Braun, G. B., She, Z.-G., Kim, D., Mann, A. P., Mölder, T., Teesalu, T., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0187-5 · Cited by 399
Staphylococcus aureus bloodstream infections: pathogenesis and regulatory mechanisms
Kwiecinski, J. M., & Horswill, A. R. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.02.005 · Cited by 373
Antibody–Drug Conjugates: The Last Decade
Joubert, N., Beck, A., Dumontet, C., & Denevault-Sabourin, C. (2020) · Pharmaceuticals · doi:10.3390/ph13090245 · Cited by 366
“To circumvent the lack of intracellular bacteria targeting associated with actual treatments, Genentech decided to develop an antibody–antibiotic conjugate (AAC), designed with a carefully selected antibody, linker and antibiotic, to achieve better activity than vancomycin for the treatment of bacteremia in vivo [124,…”
BackgroundAntibiotic resistance breakers: current approaches and future directions
Laws, M., Shaaban, A., & Rahman, K. M. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz014 · Cited by 356
Design, optimization, and nanotechnology of antimicrobial peptides: From exploration to applications
Tan, P., Fu, H., & Ma, X. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101229 · Cited by 351
Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview
Vivas, R., Barbosa, A. A. T., Dolabela, S. S., & Jain, S. (2019) · Microbial Drug Resistance · doi:10.1089/mdr.2018.0319 · Cited by 343
“Lehar et al. 134 verified that an antibody–antibiotic conjugate eliminates intracellular S. aur-eus01 , and this conjugate was superior to vancomycin for treatment of bacteraemia.”
The Role of Macrophages in Staphylococcus aureus Infection
Pidwill, G. R., Gibson, J. F., Cole, J., Renshaw, S. A., & Foster, S. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620339 · Cited by 341
Portable, On-Demand Biomolecular Manufacturing
Pardee, K., Slomovic, S., Nguyen, P. Q., Lee, J. W., Donghia, N., Burrill, D., Ferrante, T., McSorley, F. R., Furuta, Y., Vernet, A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.013 · Cited by 333
“, 2010), andbacterial infections (Kontermann, 2012), aswell as targeted delivery of antibiotics (Lehar et al., 2015).”
Mao, D., Hu, F., Kenry, Ji, S., Wu, W., Ding, D., Kong, D., & Liu, B. (2018) · Advanced Materials · doi:10.1002/adma.201706831 · Cited by 334
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections
Ma, Y., Wang, C., Li, Y., Li, J., Wan, Q., Chen, J., Tay, F. R., & Niu, L. (2020) · Advanced Science · doi:10.1002/advs.201901872 · Cited by 314
Reactive oxygen species induce antibiotic tolerance during systemic Staphylococcus aureus infection
Rowe, S. E., Wagner, N. J., Li, L., Beam, J. E., Wilkinson, A. D., Radlinski, L. C., Zhang, Q., Miao, E. A., & Conlon, B. P. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0627-y · Cited by 302
Host defense antimicrobial peptides as antibiotics: design and application strategies
Mishra, B., Reiling, S., Zarena, D., & Wang, G. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.03.014 · Cited by 299
Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
Mahalingaiah, P. K., Ciurlionis, R., Durbin, K. R., Yeager, R. L., Philip, B. K., Bawa, B., Mantena, S. R., Enright, B. P., Liguori, M. J., & Van Vleet, T. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.008 · Cited by 286
Alternative therapeutic strategies to treat antibiotic-resistant pathogens
MacNair, C. R., Rutherford, S. T., & Tan, M.-W. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00993-0 · Cited by 276
Infection microenvironment-related antibacterial nanotherapeutic strategies
Wang, Z., Liu, X., Duan, Y., & Huang, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121249 · Cited by 268
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
“[339, 340] being developed by Genentech (South San Francisco, CA, USA) that has successfully completed a phase-1 trial in healthy volunteers (NCT02596399) [341] and is currently being evaluated in a phase-I trial in patients with S.”
BackgroundIdentification and treatment of the Staphylococcus aureus reservoir in vivo
Surewaard, B. G. J., Deniset, J. F., Zemp, F. J., Amrein, M., Otto, M., Conly, J., Omri, A., Yates, R. M., & Kubes, P. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160334 · Cited by 254
Payload diversification: a key step in the development of antibody–drug conjugates
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01397-y · Cited by 257
“In addition, an A-rifamycin derivative, that demonstrated promising results in preclinical evaluation [235], has been investigated in phase 1 clinical trials in patients with Staphylococcus aureus bacteremia (NCT03162250).”
BackgroundMetformin Restores Tetracyclines Susceptibility against Multidrug Resistant Bacteria
Liu, Y., Jia, Y., Yang, K., Li, R., Xiao, X., Zhu, K., & Wang, Z. (2020) · Advanced Science · doi:10.1002/advs.201902227 · Cited by 245
Mi, G., Shi, D., Wang, M., & Webster, T. J. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800103 · Cited by 238
Osteomyelitis: Recent advances in pathophysiology and therapeutic strategies
Birt, M. C., Anderson, D. W., Bruce Toby, E., & Wang, J. (2017) · Journal of Orthopaedics · doi:10.1016/j.jor.2016.10.004 · Cited by 238
“aureus antibodyantibiotic conjugate.(99) Further advancements are needed before these new approaches can be widely accepted.”
BackgroundAntibody–Drug Conjugates—A Tutorial Review
Baah, S., Laws, M., & Rahman, K. M. (2021) · Molecules · doi:10.3390/molecules26102943 · Cited by 236
“aureus mouse infection model, an important discovery given the current global problem of antimicrobial resistance [105].”
BackgroundAnami, Y., Yamazaki, C. M., Xiong, W., Gui, X., Zhang, N., An, Z., & Tsuchikama, K. (2018) · Nature Communications · doi:10.1038/s41467-018-04982-3 · Cited by 226
Yang, S., Han, X., Yang, Y., Qiao, H., Yu, Z., Liu, Y., Wang, J., & Tang, T. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b15678 · Cited by 213
Staphylococcus aureus infection dynamics
Pollitt, E. J. G., Szkuta, P. T., Burns, N., & Foster, S. J. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007112 · Cited by 207
Inside job: Staphylococcus aureus host-pathogen interactions
Horn, J., Stelzner, K., Rudel, T., & Fraunholz, M. (2018) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2017.11.009 · Cited by 206
Fate of Antibody-Drug Conjugates in Cancer Cells
Chalouni, C., & Doll, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0667-1 · Cited by 206
Qin, L., Yang, S., Zhao, C., Yang, J., Li, F., Xu, Z., Yang, Y., Zhou, H., Li, K., Xiong, C., et al. (2024) · Bone Research · doi:10.1038/s41413-024-00332-w · Cited by 190
“93 This conjugate can bind to the cell surface and be phagocytosed into lysosomes, where active antibiotics are released under the action of proteases to kill intracellular pathogens.”
BackgroundTargeting Antibiotic Tolerance, Pathogen by Pathogen
Meylan, S., Andrews, I. W., & Collins, J. J. (2018) · Cell · doi:10.1016/j.cell.2018.01.037 · Cited by 193
“For example, antibiotic-tolerant intracellular forms of S. aureus are thought to contribute to the persistence of S. aureus bacteremia (Gresham et al., 2000; Lehar et al., 2015).”
Zhang, Y., Zhang, J., Chen, W., Angsantikul, P., Spiekermann, K. A., Fang, R. H., Gao, W., & Zhang, L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.016 · Cited by 193
Methicillin-resistant Staphylococcus aureus alters cell wall glycosylation to evade immunity
Gerlach, D., Guo, Y., De Castro, C., Kim, S.-H., Schlatterer, K., Xu, F.-F., Pereira, C., Seeberger, P. H., Ali, S., Codée, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0730-x · Cited by 188
Koch, C. D., Gladwin, M. T., Freeman, B. A., Lundberg, J. O., Weitzberg, E., & Morris, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.015 · Cited by 186
Bifunctional antimicrobial conjugates and hybrid antimicrobials
Klahn, P., & Brönstrup, M. (2017) · Natural Product Reports · doi:10.1039/c7np00006e · Cited by 181
Ricciardi, B. F., Muthukrishnan, G., Masters, E., Ninomiya, M., Lee, C. C., & Schwarz, E. M. (2018) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-018-9501-4 · Cited by 178
Clegg, J., Soldaini, E., McLoughlin, R. M., Rittenhouse, S., Bagnoli, F., & Phogat, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705360 · Cited by 177
Monoclonal antibody targeting the β-barrel assembly machine of Escherichia coli is bactericidal
Storek, K. M., Auerbach, M. R., Shi, H., Garcia, N. K., Sun, D., Nickerson, N. N., Vij, R., Lin, Z., Chiang, N., Schneider, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800043115 · Cited by 177
Ye, M., Zhao, Y., Wang, Y., Zhao, M., Yodsanit, N., Xie, R., Andes, D., & Gong, S. (2021) · Advanced Materials · doi:10.1002/adma.202006772 · Cited by 174
Construction of Single‐Iron‐Atom Nanocatalysts for Highly Efficient Catalytic Antibiotics
Huo, M., Wang, L., Zhang, H., Zhang, L., Chen, Y., & Shi, J. (2019) · Small · doi:10.1002/smll.201901834 · Cited by 173
Feng, W., Li, G., Kang, X., Wang, R., Liu, F., Zhao, D., Li, H., Bu, F., Yu, Y., Moriarty, T. F., et al. (2022) · Advanced Materials · doi:10.1002/adma.202109789 · Cited by 170
Thinking Outside the Box—Novel Antibacterials To Tackle the Resistance Crisis
Lakemeyer, M., Zhao, W., Mandl, F. A., Hammann, P., & Sieber, S. A. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201804971 · Cited by 169
Neutrophil extracellular traps enhance macrophage killing of bacterial pathogens
Monteith, A. J., Miller, J. M., Maxwell, C. N., Chazin, W. J., & Skaar, E. P. (2021) · Science Advances · doi:10.1126/sciadv.abj2101 · Cited by 166
“…in suicidal NETosis, thereby preventing intracellular bacterial replication and enhancing the antimicrobial activity of M φ s. S. aureus can survive the antimicrobial stresses of the phagosome in neutrophils ( 83 ), which provides S. aureus a long-term reservoir to replicate unperturbed ( 84 ).”
Shoaib, M., Aqib, A. I., Muzammil, I., Majeed, N., Bhutta, Z. A., Kulyar, M. F.-E.-A., Fatima, M., Zaheer, C.-N. F., Muneer, A., Murtaza, M., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1067284 · Cited by 166
Korupalli, C., Huang, C.-C., Lin, W.-C., Pan, W.-Y., Lin, P.-Y., Wan, W.-L., Li, M.-J., Chang, Y., & Sung, H.-W. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.045 · Cited by 167
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody–Drug Conjugates
Caculitan, N. G., dela Cruz Chuh, J., Ma, Y., Zhang, D., Kozak, K. R., Liu, Y., Pillow, T. H., Sadowsky, J., Cheung, T. K., Phung, Q., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2391 · Cited by 164
“Beyond ADCs, our results may also be instructive for the development of emerging therapeutics that are dependent on cleavage technologies, such as antibody–antibiotics conjugates (37, 38).”
BackgroundDevelopment of novel nanoantibiotics using an outer membrane vesicle-based drug efflux mechanism
Huang, W., Zhang, Q., Li, W., Yuan, M., Zhou, J., Hua, L., Chen, Y., Ye, C., & Ma, Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.017 · Cited by 165
Jacobs, A. J., Mongkolsapaya, J., Screaton, G. R., McShane, H., & Wilkinson, R. J. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.08.001 · Cited by 164
Protease‐activated prodrugs: strategies, challenges, and future directions
Poreba, M. (2020) · The FEBS Journal · doi:10.1111/febs.15227 · Cited by 160
Staben, L. R., Koenig, S. G., Lehar, S. M., VANDLEN, R. L., Zhang, D., Chuh, J., Yu, S., Ng, C., Guo, J., Liu, Y., et al. (2016) · Nature Chemistry · doi:10.1038/nchem.2635 · Cited by 164
Monoclonal Antibodies as an Antibacterial Approach Against Bacterial Pathogens
Zurawski, D. V., & McLendon, M. K. (2020) · Antibiotics · doi:10.3390/antibiotics9040155 · Cited by 153
“Development of this product included identifying the best antibiotic to use, identifying the linker between the antibody and antibiotic, and identifying the right place on the antibody for the linkage [66,67].”
BackgroundThe Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Sasso, J. M., Tenchov, R., Bird, R. E., Iyer, K. A., Ralhan, K., Rodríguez, Y., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00374 · Cited by 175
Self-reporting and self-regulating liquid crystals
Kim, Y., Wang, X., Mondkar, P., Büküşoğlu, E., & Abbott, N. L. (2018) · Nature · doi:10.1038/s41586-018-0098-y · Cited by 162
Natural Products That Target Virulence Factors in Antibiotic-Resistant Staphylococcus aureus
Wu, S.-C., Liu, F., Zhu, K., & Shen, J. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b05595 · Cited by 158
Yeom, J., Lee, B., Kim, D., Lee, J., Kim, S., Bae, J., Park, Y., & Lee, K. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.009 · Cited by 149
Current Status: Site-Specific Antibody Drug Conjugates
Schumacher, D., Hackenberger, C. P. R., Leonhardt, H., & Helma, J. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-016-0265-6 · Cited by 144
“This particularly includes pathogens that have previously been hard or impossible to tackle, as has recently been exemplified for novel Antibody-antibiotic conjugates targeting well-hidden, intracellular populations of pathogenic bacteria [62].”
BackgroundVancomycin Resistance in Enterococcus and Staphylococcus aureus
Li, G., Walker, M. J., & Oliveira, D. M. P. D. (2022) · Microorganisms · doi:10.3390/microorganisms11010024 · Cited by 182
Bacterial outer membrane vesicles as potential biological nanomaterials for antibacterial therapy
Huang, W., Meng, L., Chen, Y., Dong, Z., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.12.005 · Cited by 154
Synthetic macromolecules as therapeutics that overcome resistance in cancer and microbial infection
Tan, J., Tay, J., Hedrick, J. L., & Yang, Y. Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120078 · Cited by 149
Gao, F., Xu, L., Yang, B., Fan, F., & Yang, L. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00212 · Cited by 143
Wall Teichoic Acid in Staphylococcus aureus Host Interaction
van Dalen, R., Peschel, A., & van Sorge, N. M. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.05.017 · Cited by 140
Novel targets to develop new antibacterial agents and novel alternatives to antibacterial agents
Belete, T. M. (2019) · Human Microbiome Journal · doi:10.1016/j.humic.2019.01.001 · Cited by 158
He, S., Huang, J., Zhang, Q., Zhao, W., Xu, Z., & Zhang, W. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202105198 · Cited by 141
Ercoli, G., Fernandes, V. E., Chung, W. Y., Wanford, J. J., Thomson, S., Bayliss, C. D., Straatman, K. R., Crocker, P. R., Dennison, A. R., Martínez‐Pomares, L., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0147-1 · Cited by 149
Antibody–Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections
Mariathasan, S., & Tan, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.008 · Cited by 146
Hu, D., Zou, L., Yu, W., Jia, F., Han, H., Yao, K., Jin, Q., & Ji, J. (2020) · Advanced Science · doi:10.1002/advs.202000398 · Cited by 136
An AIEgen‐Peptide Conjugate as a Phototheranostic Agent for Phagosome‐Entrapped Bacteria
Qi, G., Hu, F., Kenry, Shi, L., Wu, M., & Liu, B. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201906099 · Cited by 133
Munguia, J., & Nizet, V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.003 · Cited by 144
“conjugated to an antibiotic (rifalogue) activated only after it is released in the proteolytic environment of the phagolysosome [21].”
Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species
Andrianaki, A. M., Kyrmizi, I., Thanopoulou, K., Baldin, C., Drakos, E., Soliman, S. S. M., Shetty, A. C., McCracken, C., Akoumianaki, T., Stylianou, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05820-2 · Cited by 132
Towards Robust Delivery of Antimicrobial Peptides to Combat Bacterial Resistance
Drayton, M., Kizhakkedathu, J. N., & Straus, S. K. (2020) · Molecules · doi:10.3390/molecules25133048 · Cited by 145
“reside within the cell for prolonged periods of time [56,58].”
BackgroundInfluentialGlycomimetics for the inhibition and modulation of lectins
Leusmann, S., Ménová, P., Shanina, E., Titz, A., & Rademacher, C. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00954d · Cited by 142
Future Antibacterial Strategies: From Basic Concepts to Clinical Challenges
Cattoir, V., & Felden, B. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz134 · Cited by 138
“10 intracellular proteases cleave the internal linker and release the active antibiotic [31].”
BackgroundYang, X., Shi, G., Guo, J. J., Wang, C., & He, Y. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s179380 · Cited by 138
“It has been reported that treatment of patients with invasive MRSA infections with conventional antibiotics has a failure rate of up to 50% and measurable outgrowth of antibiotic-resistant strains is not observable in most cases.(17) Although considered an extracellular pathogen, S.”
BackgroundMethodHost Defense Peptides: Dual Antimicrobial and Immunomodulatory Action
Drayton, M., Deisinger, J. P., Ludwig, K. C., Raheem, N., Müller, A., Schneider, T., & Straus, S. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011172 · Cited by 141
“A number of drug delivery vehicles showing potential for HDP formulation include lipid encapsulations [113,114], metal nanoparticles [115–118], synthetic polymers [74,119–123] and natural biomolecules, such as polysaccharides [124–128], polypeptides [129,130], antibodies [131] and DNA nanostructures [132,133].”
BackgroundPrinciples of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases
Naran, K., Nundalall, T., Chetty, S., & Barth, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03158 · Cited by 154
Staphylococci evade the innate immune response by disarming neutrophils and forming biofilms
de Vor, L., Rooijakkers, S. H. M., & van Strijp, J. A. G. (2020) · FEBS Letters · doi:10.1002/1873-3468.13767 · Cited by 138
Staphylococcal protein A inhibits complement activation by interfering with IgG hexamer formation
Cruz, A. R., den Boer, M. A., Strasser, J., Zwarthoff, S. A., Beurskens, F. J. M., de Haas, C. J. C., Aerts, P. C., Wang, G., de Jong, R. N., Bagnoli, F., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2016772118 · Cited by 137
“NewmanΔspa/sbi was labeled with a human monoclonal antibody directed against wall teichoic acid (WTA) (Lehar et al, 2015), a highly abundant anionic glycopolymer that is covalently anchored to the peptidoglycan layer (Brown et al, 2013).”
MethodHost defense mechanisms against Mycobacterium tuberculosis
Chai, Q., Lü, Z., & Liu, C. H. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03353-5 · Cited by 146
“Growing experimental evidence supports an essential role for B cells and antibodies in protecting hosts against multiple intracellular bacteria, such as Francisella tularensis [135], Salmonella typhimurium [136], and Staphylococcus aureus [137], which have reignited the interest to revisit the role of B cells and the…”
BackgroundZhang, S., Yang, H., Wang, M., Mantovani, D., Yang, K., Witte, F., Tan, L., Yue, B., & Qu, X. (2023) · The Innovation · doi:10.1016/j.xinn.2023.100503 · Cited by 154
“143 Therefore, further studies using multi-omics and biomaterial technologies are needed to improve the cell speci-fi city of biomaterials for the targeted removal of intracellular bacteria.”
Battle against Vancomycin-Resistant Bacteria: Recent Developments in Chemical Strategies
Dhanda, G., Sarkar, P., Samaddar, S., & Haldar, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01093 · Cited by 121
Antibody Conjugates-Recent Advances and Future Innovations
Leung, D., Wurst, J., Liu, T., Martinez, R., Datta‐Mannan, A., & Feng, Y. (2020) · Antibodies · doi:10.3390/antib9010002 · Cited by 125
“aureus antibody which demonstrated marked clearance of latent bacteria reservoirs thought to be the cause of recurring infection [41].”
BackgroundStrategies and progresses for enhancing targeted antibiotic delivery
Nazli, A., He, D. L., Liao, D., Khan, M. Z. I., Huang, C., & He, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114502 · Cited by 124
Peck, M., Rothenberg, M. E., Deng, R., Lewin-Koh, N., She, G., Kamath, A. V., Carrasco-Triguero, M., Saad, O., Castro, A., Teufel, L., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02588-18 · Cited by 108
“aureus bacteria that are not adequately eliminated by current SOC antibiotics (14, 19).”
BackgroundInfluential
Metadata
- Authors
- Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., Kim, J., Park, S., Darwish, M., Lee, B.-C., Hernandez, H., Loyet, K. M., Lupardus, P., Fong, R., Yan, D., Chalouni, C., Luis, E., Khalfin, Y., Plise, E., Cheong, J., Lyssikatos, J. P., Strandh, M., Koefoed, K., Andersen, P. S., Flygare, J. A., Wah Tan, M., Brown, E. J., & Mariathasan, S.
- Affiliations
- Genentech (US)
- Symphogen (Denmark) (DK)
- Corresponding author
- Brown, Eric J.
- Mariathasan, Sanjeev
- ORCID
- Venue
- Nature
- Published
- 2015-11
- Volume
- 527
- Issue
- 7578
- Pages
- 323-328
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1915856409
- Cited by
- 838
- References
- 45
- Citations by year
- 2026: 53 · 2025: 80 · 2024: 72 · 2023: 89 · 2022: 88 · 2021: 79 · 2020: 86 · 2019: 92 · 2018: 85 · 2017: 64 · 2016: 43 · 2015: 5
- FWCI
- 51.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Structural Characterization
- Keywords
- Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, antibiotic resistance, bacteremia, phagolysosomes, wall teichoic acid, vancomycin, host cell internalization, antibiotic delivery
- MeSH terms
- Animals, Anti-Bacterial Agents, Carrier State, Female, Microbial Sensitivity Tests, Phagosomes, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Drug Design, Bacteremia, Immunoconjugates, Intracellular Space, Mice, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.